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Placebo Surgery in Trials of Therapy 
for Parkinson’s Disease
 
To the Editor:
 
 The Sounding Board articles by Freeman
et al.
 
1
 
 and Macklin
 
2
 
 (Sept. 23 issue) provided an excellent
discussion of sham surgery for patients with Parkinson’s dis-
ease. However, Freeman et al. seem overenthusiastic about
downplaying the risks of sham surgery. Their statement that
these procedures are easier to perform, standardize, and re-
produce than traditional surgical procedures does not do
justice to the neurosurgical skills involved in performing
stereotactic brain surgery. It is probable that the wide range
of outcomes regarding the effectiveness of and morbidity
associated with pallidotomy is related to the varying skills
of the operating neurosurgeon.
Freeman et al. present the cogent argument that sham
surgery is the only solution for proving the validity of the
neurosurgical procedures discussed in relation to Parkin-
son’s disease. Not only are there important clinical ques-
tions that need to be answered, but society also needs to
know whether any surgical therapy for Parkinson’s disease
provides substantial enduring benefit.
Macklin is no doubt correct that the informed-consent
process is less than perfect. Rather than turn our backs on
objectively evaluating surgical procedures, however, we
should be more diligent in obtaining consent. In the end,
the patients with Parkinson’s disease who give informed
and valid consent to participate in trials in which sham sur-
gery is used are truly brave pioneers who are helping to
advance the frontier of research. We should not prevent such
trials from taking place.
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To the Editor:
 
 Macklin’s argument against sham surgery
in clinical research is fundamentally flawed in two impor-
tant respects. First, there is no ethical requirement to min-
imize absolutely the risk of harm to research subjects. The
ethical requirements are that there be a reasonable balance
between the potential risks and the potential benefits to
the subject or to society
 
1
 
 and that the subject make a fully
informed choice about participating in the research.
 
2
 
 With-
in the context of a reasonable overall risk–benefit ratio, risks
should be minimized by using medically and scientifically
appropriate procedures.
 
1
 
Second, preventing subjects from deciding what risks
they are willing to take is a direct violation of the principle
of autonomy. We should not declare research unethical be-
cause the process of informed consent can be imperfect;
instead, we should concentrate on improving that process.
Medical paternalism, in which physicians decide what risks
to expose patients to, is ethically unacceptable. A medical
maternalism in which research subjects are protected from
all risks and from the autonomous exercise of their right
to choose is no better.
(The opinions expressed in this letter are those of the
author and do not necessarily represent the policy of the
Department of Veterans Affairs.)
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To the Editor:
 
 In 1993, when we proposed the idea of a
double-blind design for fetal-cell transplantation for Parkin-
son’s disease, our plan was met with a good deal of skep-
ticism by members of the scientific community, including
Dr. Freeman’s coauthor Dr. Olanow.
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 Because no neuro-
surgical trial had been performed with a double-blind de-
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sign, it was unclear whether such a protocol could or
should be carried out. Our double-blind study of 40 pa-
tients (20 patients who received implants and 20 control
subjects) has been completed.
 
2,3
 
It is particularly challenging to do a double-blind surgi-
cal study in patients with Parkinson’s disease. Because it
would be unethical to discontinue antiparkinsonian drugs
in these patients, neurotransplants have to add substantial-
ly to the best pharmacologic treatment of each patient. It is
likely, though not sure, that the effects of transplantation
would be much easier to demonstrate in a placebo-con-
trolled design in which the placebo group did not receive
drug therapy. Because of the great value of levodopa and
other drugs, such a placebo design could not be justified.
Double-blind studies are undertaken to demonstrate the val-
ue of a treatment in a small group of patients with reason-
able, but not zero, risk. In our study, the patients who re-
ceived implants were exposed to more risk than the patients
who had placebo surgery, because of needle penetrations of
the brain. Whether the patients who received implants ben-
efited more than the patients who underwent placebo sur-
gery could be answered only with the double-blind design.
We were not surprised that our design produced con-
troversy seven years ago. Even as discussion continues about
the role of double-blind surgical studies, review groups of
the Food and Drug Administration and National Institutes
of Health have embraced the concept, and several such
studies are now under way.
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To the Editor:
 
 Macklin states, “An alternative research
design that did not involve sham surgery . . . would be
less rigorous from a methodologic point of view.” That a
placebo procedure in a clinical trial be manifestly harmless
is not only an ethical requirement but also a fundamental
requirement for clinically relevant, generalizable inferences
to be drawn from the trial. Even if the implanted material is
found to improve the patient’s condition, it may not fully
counter any damage that may have occurred as a result of
the surgery. In other words, a positive effect of treatment
in a trial involving a potentially harmful control may result
in the adoption into clinical practice of a treatment that
results in more harm to patients than if they had received
no intervention at all.
Some may argue that a trial that compares a treatment
involving surgery and implantation with conservative man-
agement and finds a beneficial effect also admits the pos-
sibility that the implantation itself added nothing to, or
even detracted from, a beneficial placebo effect. If this is
truly a possibility, then perhaps the three-group trial that
Macklin describes at the end of her article is the only clin-
ically informative option. However, the assumption that
sham surgery is likely to have a positive effect on health
requires careful examination.
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To the Editor:
 
 The advantages of a new treatment are of-
ten vastly overestimated, in spite of the most objectively
written notice of information, as a result of the combined
effects of the physician-investigator’s expectations and the
patient’s hopes. Therefore, many patients not only agree
to participate but also eagerly desire participation in stud-
ies of such treatments, which represent the only hope of-
fered to them. Under these circumstances it is likely that
the consent will not really be freely given, and therefore
the study may not be ethically acceptable.
I suggest the following solution: when participation in
a randomized study with a sham-procedure group is pro-
posed to a patient, the patient must be offered, in addition
to the alternative of agreeing or refusing to participate in
the randomized study, the possibility of receiving the new
experimental treatment without participating in the ran-
domized study. Obviously, when offered this choice, fewer
patients will agree to enter the study. However, if the in-
vestigator presents the possible outcome in a realistic way,
with all the uncertainties about the outcome of the new
treatment, some patients will agree to participate for purely
altruistic reasons, and even more patients will want to par-
ticipate if all the patients are offered the possibility of re-
ceiving the new treatment later if it is proved to be effective.
This design will force the investigator to present the pos-
sible outcomes of the two groups of the study in a realistic
and balanced way: if the investigator exaggerates the ex-
pected benefits of the new treatment, no patients will agree
to participate in the randomized study. This approach would
make the recruitment of patients more difficult, but there
are good reasons why this type of study should not be easy
to carry out.
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The authors reply:
 
To the Editor:
 
 It is affirming to note that all the corre-
spondents support the use of placebo-surgery controls un-
der certain conditions. We agree with Burris that it is neither
required nor reasonable to expect surgical trials to involve
no risk. As with all trials, patients must be informed of the
potential risks, and risks must be reasonable in relation to
the possible benefits to the individual patient as well as to
society.
 
1-3
 
 We believe it is a mistake to hold surgical trials
to a standard more stringent than that required for the
study of nonsurgical interventions.
Horisberger recommends that patients be offered access
to the experimental treatment without participating in the
study in order to minimize exaggerated estimates of ben-
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efit and to ensure that informed consent is freely given.
Offering the patient such access to an unproved interven-
tion implies that the investigator condones the procedure
and that it is beneficial when this is not known to be the
case. It would therefore serve to exaggerate benefit and to
induce a less informed decision about receiving the inter-
vention. We believe it is inappropriate for an investigator
to offer an intervention as a therapy while at the same time
asserting that it is necessary to perform a placebo-controlled
trial to determine whether it is effective.
We agree with Weiner that differences in surgical meth-
ods and skills can affect the outcome of surgical procedures.
However, it is easier to standardize surgical methods used
with nonablative and minimally invasive procedures, as in
the case of cellular transplantation. It is because of the vari-
ability that can occur even with a single surgeon that ran-
domized clinical trials are necessary.
 
4
 
Freed et al. assert that we were skeptical about the use of
a placebo control in their trial design. Rather, we argued for
multiple trials in which different variables with regard to
transplantation were used, so that negative or inconclusive
results with a single protocol would not adversely affect the
entire field.
 
5
 
 We were not opposed to the use of placebo
controls. In our article, we cited numerous examples of such
studies (including neurosurgical trials) that predated both
of our trials.
Our concern is that patients may undergo operations per-
formed by surgeons who stand to benefit financially, aca-
demically, and by reputation but who fail to disclose that
the operations have unproved benefits and undefined risks.
If the safety and efficacy of a new surgical procedure are not
established in controlled trials involving patients who give
informed consent, thousands of future patients may be sub-
jected to the risks and costs of an unproved operation in un-
controlled studies, without their full knowledge and consent.
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To the Editor:
 
 The claim that my argument against sham
surgery in clinical research is “fundamentally flawed in two
important respects” is mistaken on both counts. Burris
contends that “there is no ethical requirement to minimize
absolutely the risk of harm to research subjects.” I do not
know what he intends by “absolutely”; it is a term without
meaning in this context. However, a look at the U.S. Code
of Federal Regulations reveals the following as the first of
the requirements that institutional review boards must de-
termine are satisfied in order to approve research: “Risks
to subjects are minimized.”
 
1
 
The second alleged flaw is that “preventing subjects from
deciding what risks they are willing to take is a direct vio-
lation of the principle of autonomy.” But the role of the
institutional review board in our system for the protection
of human subjects is precisely to determine the acceptabil-
ity of risks. Once the institutional review board has deter-
mined that risks to subjects are minimized and that “risks
to subjects are reasonable in relation to anticipated bene-
fits,”
 
1
 
 then potential subjects are asked to provide their vol-
untary, informed consent. If subjects’ informed consent
were the only ethical requirement for research, there would
be no need for institutional review boards to make risk–
benefit determinations before approving research protocols.
Weiner endorses the view that “sham surgery is the only
solution for proving the validity of the neurosurgical pro-
cedures” and concludes that we should not prevent such
trials from taking place. Although I acknowledge that us-
ing sham surgery as a control may be the best way to seek
proof, it is not the only “objective” way to demonstrate ef-
ficacy. There are other, albeit less rigorous, ways. Slattery
questions whether it is even the best way, since harm pro-
duced in a control group of a trial prevents investigators
from determining whether there is a benefit from the ex-
perimental treatment.
Freed et al. note that review groups of the Food and
Drug Administration and National Institutes of Health
have embraced the concept of trials that involve sham sur-
gery and that several such studies are under way. This means
that the trials were approved by institutional review boards,
an important procedural requirement in our system for the
protection of human subjects. However, approval by an in-
stitutional review board does not make a study ethically
acceptable. It is evidence only that the institutional review
board found the research to be ethically acceptable, a judg-
ment with which another institutional review board might
reasonably disagree.
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Outbreaks of Enterovirus 71 Infection
 
To the Editor:
 
 The outbreak of enterovirus 71 infection
in Taiwan, reported by Ho et al. (Sept. 23 issue),
 
1
 
 occurred
almost a year after the outbreak in Malaysia. Though both
outbreaks occurred in Asia and both involved large num-
bers of deaths, it was not known whether the two out-
breaks were related. We studied the nucleotide sequence
and secondary RNA structure of some of the isolates, us-
ing the sequence of the 5' untranslated region (UTR).
Enterovirus 71 isolates from patients in Singapore (sev-
en isolates), Taiwan (two isolates), and Japan (one isolate)
were examined and compared with those previously report-
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ed in Malaysia
 
2,3
 
 or with sequences deposited in GenBank.
A phylogenetic tree that we constructed using the aligned
5' UTR sequences revealed at least two major clusters of
enterovirus 71 isolates. Cluster 1 included the isolate from
Japan and six of the seven isolates from Singapore, togeth-
er with isolates found predominantly in Malaysia during
the 1997 outbreak. The isolates in this cluster had at least
89 percent sequence homology with enterovirus 71 MS
isolates. The isolates in cluster 1 formed two subclusters.
The isolate from Japan and five of the six isolates from Sin-
gapore were clustered with isolates from the Malaysian pen-
insula, forming one subcluster, and the remaining isolates,
which included others from the Malaysian peninsula, Sa-
rawak, and Singapore, formed the other subcluster.
Three other isolates examined, one from Singapore and
two from Taiwan, were in cluster 2, which consisted mostly
of isolates from the 1998 outbreak in Taiwan. Cluster 2 also
had two subclusters, with all the isolates from Taiwan, in-
cluding the two sequenced in this study, in one subcluster
and the remaining isolates from the Malaysian peninsula and
Singapore in the other. The isolates in these two subclus-
ters had at least 97 percent homology with each other and
approximately 85 percent homology with the coxsackievirus
A9 5' UTR sequence rather than with the enterovirus 71
MS group, which contained the other enterovirus 71 strains
found predominantly in Malaysia and Singapore. A com-
parison of the 5' UTR secondary RNA structure, which has
been associated with the degree of virulence, in the cluster
2 isolates revealed no significant differences in the struc-
ture of the three domains within the 5' UTR sequence.
These findings suggest that the 5' UTR features of the
enterovirus 71 strains from the Taiwanese outbreak were al-
most identical to those of the coxsackievirus A9–like strains
isolated previously in the Malaysian peninsula.
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 Because of
these similarities and the high frequency of travel between
Malaysia and Taiwan, it is tempting to speculate that the
predominant enterovirus 71 strains in the Taiwanese out-
break may have been accidental imports.
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The authors reply:
 
To the Editor:
 
 In response to AbuBakar et al., we refer
first to a phylogenetic study of enterovirus 71 isolates from
1997 and 1998, reported by Shimizu et al.,
 
1
 
 in which one
of us participated as a coinvestigator. Eleven isolates from
Japan, 5 from Malaysia, and 13 from Taiwan were analyzed.
The isolates were classified as genotype group A (subgroup
A
 
1
 
 or A
 
2
 
) or genotype group B. Six strains from Japan,
1 strain from Malaysia, and 10 strains from Taiwan were
in group B, and 5, 4, and 3 strains, respectively, were in
group A (subgroup A
 
2
 
). Although the isolates were not
homogeneous, the majority of the Malaysian isolates were
in group A, whereas the Taiwanese isolates were in group B.
Shimizu et al. arrived at this classification by analyzing
the VP4 and VP2 regions.
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 By analyzing, as did AbuBakar
et al., the 5' noncoding region, two of us also found that
the majority of the Taiwanese and Malaysian strains were
clustered in different groups. In a study of 60 enterovirus
71 isolates from patients in various parts of Taiwan, one of
us found that only 5 isolates were in group A, whereas 55
were clustered in group B.
To date, enterovirus 71 group B consists mainly of Jap-
anese and Taiwanese isolates of recent origin. It is unclear
whether the Malaysian isolates studied by AbuBakar and
colleagues have been available to other investigators. If they
have not been available, many of the Malaysian isolates, con-
trary to our findings and those of Shimizu et al.,
 
1
 
 may be-
long to group B. If this is the case, the findings of AbuBakar
et al. need to be confirmed, and more strains should be
studied. Even so, it would not be possible to conclude that
the Taiwanese strains came from Malaysia. They could just
as well have come from Japan. It is premature to reach def-
inite conclusions about the precise geographic movements
of the Japanese, Malaysian, and Taiwanese strains.
We and our coauthors, many of whom are in the Taiwan
Department of Health, would like to acknowledge with grat-
itude the assistance of the Centers for Disease Control and
Prevention in the investigation of the enterovirus 71 epidem-
ic in Taiwan. Specifically, we would like to thank Drs. An-
thony W. Mounts, Umesh P. Parashar, and Wun-Ju Shieh of
the investigative team, who were in Taiwan in June 1998.
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Enterovirus 71 Infection and Neurologic 
Complications
 
To the Editor:
 
 In their article on neurologic complications
associated with enterovirus 71 infection, Huang et al. (Sept.
23 issue)
 
1
 
 reported the presence of severe brain-stem lesions,
as evidenced by findings on magnetic resonance imaging in
many patients and by autopsy findings in one. Our own
pathological findings (unpublished data), based on a detailed
autopsy examination of four patients,
 
2
 
 also showed inflam-
mation confined to the gray matter of the spinal cord and
medulla and the tegmentum of the midbrain and pons. In
all our patients, as in theirs, there was no inflammation in
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pontine nuclei. We noted inflammation in the dentate nu-
cleus, hypothalamus, and thalamus but not in the cerebrum.
The reason for this distribution of inflammation is un-
known, but it may be related to the predilection of enter-
ovirus 71 for specific neurons. Another possibility is that the
virus may enter the central nervous system by way of the
peripheral cranial and spinal nerves and infect the neurons
it first encounters in the tegmentum of the brain stem and
the gray matter of the spinal cord before spreading along
neuronal pathways. Interestingly, this pattern of inflamma-
tion appears to be similar to that of bulbar poliomyelitis,
in which there is also involvement of the tegmentum of the
brain stem but not of the anterior pons.
 
3
 
 However, although
we noted that the inferior olives were inflamed, Bodian
described the absence of inflammation in these areas in pa-
tients with bulbar poliomyelitis.
 
3 Thus, in addition to neu-
rologic and other manifestations,1 pathological features also
appear to distinguish encephalitis of the brain stem caused
by enterovirus 71 infection from bulbar poliomyelitis.
To strengthen the causal link between enterovirus 71 in-
fection and encephalitis further, immunolocalization of vi-
ral antigens in inflamed tissues of the central nervous system
was performed, and positive neuronal staining was obtained
in our four patients.4 Direct localization, by immunohis-
tochemical methods or other means, is essential in order
to confirm the presence of encephalitis caused by entero-
virus 71 infection. In the series of Huang et al., only two
patients had virus isolated from a clinically relevant site —
the cerebrospinal fluid in one and tissues of the central
nervous system in the other.1 In a majority of their patients
(95 percent), isolates of enterovirus 71 were obtained from
the throat and rectum. In a major epidemic, such as the one
in Taiwan, patients with other types of fulminant viral en-
cephalitis (e.g., Japanese encephalitis) could be identified
inadvertently, and the enterovirus 71 isolated from a periph-
eral site could, in fact, be nonpathogenic.
We agree with Huang et al. that the children with en-
cephalitis of the brain stem caused by enterovirus 71 prob-
ably died as a result of neurogenic pulmonary edema due
to destruction of the medulla.2,5 There was no histologic
evidence of myocarditis in any of the cases we examined.
KUM THONG WONG, M.B., B.S., M.R.C.PATH.
LUCY CHAI SEE LUM, M.B., B.S., M.R.C.P.
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The authors reply:
To the Editor: The biphasic clinical manifestation of en-
terovirus 71 infection that we saw, with a prodrome of
hand-foot-and-mouth disease or herpangina that lasted an
average of 3.2 days followed by neurologic manifestations,
clearly indicates the causal link between enterovirus 71 in-
fection and disorders of the central nervous system. Indeed,
66 percent of our patients had isolates of enterovirus 71
obtained from throat swabs, 44 percent had isolates ob-
tained from stool specimens, and only 5 percent had iso-
lates obtained from cerebrospinal fluid or brain tissue. Very
low rates of virus isolation in cerebrospinal fluid, ranging
from 0 to 3 percent, were reported in previous outbreaks
of enterovirus 71 infection in Bulgaria, Hungary, Japan,
and Australia.1 With poliovirus infections, the virus is also
only occasionally recovered from cerebrospinal fluid. The
diagnosis of poliomyelitis is often established on the basis of
a virus recovered from a peripheral site, such as the throat
or rectum.2,3 We believe that the diagnosis of enterovirus
71–related infection of the central nervous system may be
established in a similar manner. Moreover, we found high
titers in our patients of enterovirus 71–specific antibody by
means of a neutralization test (data not shown), which is
additional evidence of recent enterovirus 71 infection. We
also demonstrated by immunohistochemical methods that
enterovirus 71 antigens were present in the brain-stem tis-
sue of the patient who underwent autopsy.
Because of the effective nationwide vaccination program,
an epidemic of Japanese encephalitis is no longer a cause of
major concern for Taiwanese children. The clinical manifes-
tations of Japanese encephalitis include nuchal rigidity, opis-
thotonos, dystonia, rigidity, convulsions, coma, and coarse
tremors, which differ from the symptoms largely affecting
the brain stem in our patients with enterovirus 71 infec-
tion. The majority of the survivors of Japanese encephali-
tis have mental retardation, seizure disorders, motor deficits,
or subtle behavioral and intellectual abnormalities, effects
that are quite different from those caused by enterovirus 71
infection. The characteristic findings on magnetic resonance
imaging that are associated with Japanese encephalitis in-
clude lesions of the thalamus, basal ganglia, and hippocam-
pus,4 again in contrast with the predominant involvement
of the brain stem, especially the pontine tegmentum, in pa-
tients with enterovirus 71 infection. We believe that the
presence of hand-foot-and-mouth disease or herpangina,
myoclonus, cerebellar and oculomotor signs, and charac-
teristic findings on magnetic resonance imaging in the brain
stem all help to distinguish rhombencephalitis caused by
enterovirus 71 infection from Japanese encephalitis and
other viral infections, such as bulbar poliomyelitis. We found
no evidence that Japanese encephalitis had contributed to
the involvement of the central nervous system in our patients
with culture-confirmed enterovirus 71 infection, although
serologic testing for the presence of Japanese encephalitis
was not performed.
CHAO-CHING HUANG, M.D.
CHING-CHUAN LIU, M.D., M.P.H.
National Cheng Kung University
Tainan 704, Taiwan
YING-CHAO CHANG, M.D.
Chang Gung Children’s Hospital
Kaohsiung 833, Taiwan
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Acute Myeloid Leukemia
To the Editor: In their otherwise informative review of
new developments in the diagnosis and treatment of acute
myeloid leukemia (AML), Löwenberg and colleagues (Sept.
30 issue)1 state that before the 1970s, the five-year survival
rate among patients with AML was less than 15 percent but
that survival among patients under the age of 65 years is
currently 40 percent. These statistics differ markedly from
U.S. population–based survival rates among patients with
AML from the Surveillance, Epidemiology, and End Re-
sults (SEER) program of the National Cancer Institute,2 a
consortium of 11 geographically defined cancer registries.
Data from the SEER program indicate that five-year over-
all (observed) survival among all patients with AML was
5 percent for patients given a diagnosis in the mid-1970s,
the earliest period for which data are available (Table 1). Al-
though this survival rate has improved steadily over time, it
reached only 11 percent for patients given a diagnosis in the
most recent years for which five-year follow-up is complete
(1988 to 1991). Moreover, for patients under the age of 65,
the most recent five-year survival rate was 21 percent, ac-
cording to the data from the SEER program — about half
that cited for this age group by Löwenberg and colleagues
(although they did not specify whether they were report-
ing a five-year overall rate).
Table 1 also highlights the striking association between
age and survival among patients with AML. Over the past
20 years, improvements in survival have been realized almost
entirely by persons under the age of 65, with equivalent
gains among patients up to 19 years old and those 20 to 64
years old. In contrast, five-year observed survival is exceed-
ingly poor and has not improved with time among patients
65 and older, who account for half of all cases of AML.
Löwenberg et al. do not give the source of the survival
rates presented in their review. If these statistics were derived
from a clinical setting, they may very well be more favor-
able than those observed in a geographically defined area,
which summarize outcomes of disease among an entire pop-
ulation. With regard to general observations about the out-
come of cancer, survival data from the population-based
SEER program have the distinct advantages of large num-
bers of patients, uniform follow-up, and demographic rep-
resentativeness. In addition, up-to-date data on incidence
and survival can be obtained easily through the Internet at
http://www-seer.ims.nci.nih.gov.
Regardless of the source of the data, the survival statis-
tics for patients with AML convey the fact that grave out-
comes continue to be associated with this disease, partic-
ularly in older patients.
CHRISTINA A. CLARKE, PH.D.
SALLY L. GLASER, PH.D.
Northern California Cancer Center
Union City, CA 94587
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The authors reply:
To the Editor: Drs. Clarke and Glaser raise the important
issue of difference in survival rates between patients in the
general population who are given a diagnosis of acute my-
eloid leukemia and those who are enrolled in clinical trials.
They suggest that a survival rate of 40 percent for patients
under the age of 65 years is overly optimistic.
We agree that most published data on survival among pa-
tients with AML are derived from clinical trials and that
there are too few population-based data available. This issue
has been addressed in a limited way by Stiller et al. through
regional surveys of patients under 30 years of age in the
United Kingdom.1 The population survival rate is virtually
the same as that among the patients enrolled in the national
trial2— 42 percent at 5 years and 39 percent at 10 years.
There was no difference in survival between patients who
were enrolled in the national trial and those who were not
— possibly because patients who were not enrolled tended
to follow the schedule of the trial. A high proportion of
younger patients (<55 years old) in the United Kingdom
entered the national trial.
Data from the Netherlands Cancer Registry obtained
during the period from 1989 through 1995 indicate five-
year survival rates among patients with AML of 47 percent
(for those up to 14 years of age) and 30 percent (for those
15 to 19 years of age).3 We agree that these data are incom-
plete and that there has been little evidence of improved
survival among older patients. In the Netherlands, patients
are usually not offered suitable treatment in a trial and are
usually treated according to a more obviously palliative ap-
proach. Data from trials involving older patients are relevant
only to the minority of patients who are considered suit-
able for entry into the trials, and the results derived are not
*Data were obtained from the Surveillance, Epidemiology, and End Re-
sults program.2 All patients were followed through 1996. The number of
patients represents the total number of patients at the beginning of the
five-year period in question, and the percentage represents the percentage
surviving after five years.
TABLE 1. FIVE-YEAR OVERALL SURVIVAL RATES AMONG PATIENTS 
WITH ACUTE MYELOID LEUKEMIA, ACCORDING TO AGE
AND YEAR OF DIAGNOSIS.*
AGE AT
DIAGNOSIS YEAR OF DIAGNOSIS
1973–1977 1978–1982 1983–1987 1988–1991
total no. of patients (% surviving)
«19 yr 192 (18) 162 (25) 143 (32) 133 (40)
20–64 yr 1016 (6) 1015 (10) 1044 (15) 838 (18)
»65 yr 1055 (2) 1170 (1) 1255 (1) 1118 (2)
Total 2263 (5) 2347 (7) 2442 (9) 2089 (11)
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always applicable to the majority who do not enter such
trials. It is also difficult to find evidence of improvement
in survival among older patients who do not enter trials.
BOB LÖWENBERG, M.D.
University Hospital Rotterdam
3008 AE Rotterdam, the Netherlands
ALAN K. BURNETT, M.D.
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Growth Hormone Therapy in Adults 
and Children
To the Editor: In their review of growth hormone ther-
apy (Oct. 14 issue),1 Vance and Mauras do not mention the
abuse of growth hormone by adults. Physicians should be
aware that this phenomenon is well documented in athletes.2
Abuse by physicians is also of concern. My organization has
intervened in several cases in which physicians have taken
growth hormone to increase their sense of well-being and
physical performance.
JOHN A. FROMSON, M.D.
Massachusetts Medical Society
Waltham, MA 02451
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To the Editor: Vance and Mauras note that children with
Down’s syndrome, Noonan’s syndrome, the Prader–Willi
syndrome, or other conditions may have short stature. If
so, should they be denied the benefits of growth hormone
therapy? The authors’ only stated objection is that no stud-
ies have prospectively assessed linear growth in children with
these conditions until the achievement of final height. How-
ever, as the authors note, growth hormone therapy has not
been proved to increase final height in children with chronic
renal insufficiency, yet that diagnosis is an approved indi-
cation for treatment with growth hormone.
Is growth hormone too expensive to give to children
with mental deficiency or developmental defects? Why is
growth hormone therapy for children with chronic renal
insufficiency or Turner’s syndrome — conditions in which
only a minority of patients have growth hormone insuffi-
ciency — more acceptable than it is for patients whose short
stature is associated with other conditions?
RICHARD A. LEVY, M.D.
Rush–Presbyterian–St. Luke’s Medical Center
Chicago, IL 60612
The authors reply:
To the Editor: There is no scientific evidence that admin-
istration of growth hormone has any beneficial effects in
anyone with normal pituitary function. That some physi-
cians take growth hormone is not surprising, since physi-
cians are not immune to the unsubstantiated claims that it
improves well-being and physical performance.
The Prader–Willi syndrome, Down’s syndrome, and
Noonan’s syndrome are some of the many congenital con-
ditions that impair linear growth and for which growth hor-
mone therapy has been tried. In children with Down’s
syndrome, treatment for three years resulted in improved
linear growth, but there was no change in either head cir-
cumference or intellectual function.1 Children with Noon-
an’s syndrome have had increases in growth in response to
growth hormone therapy for up to four years; the respons-
es were intermediate between those in children with idio-
pathic growth hormone deficiency and those with Turner’s
syndrome.2,3 In children with the Prader–Willi syndrome,
treatment with growth hormone for up to two years re-
sulted in improved linear growth, decreased body fat, and
increased lean body mass.4,5 The duration of all these stud-
ies was limited, and they were not well controlled. One must
be cautious not to raise parental expectations of greater
height until the results of large, long-term, well-controlled
studies of growth hormone therapy in children with these
conditions are available.
MARY LEE VANCE, M.D.
University of Virginia Health System
Charlottesville, VA 22908
NELLY MAURAS, M.D.
Nemours Children’s Clinic
Jacksonville, FL 32207
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Acute Eosinophilic Hepatitis from Trovafloxacin
To the Editor: According to the Food and Drug Admin-
istration, trovafloxacin, a broad-spectrum quinolone anti-
biotic, has been associated with more than 100 cases of he-
patic toxicity. Fourteen of these cases involved acute liver
failure, with transplantation required in four patients; five
patients died of liver disease. More than 300,000 prescrip-
tions for trovafloxacin were written monthly in the United
States before use of the drug was limited to certain serious
infections in an inpatient setting.
There have been a few reports of hepatic toxicity asso-
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ciated with the use of quinolones1-3 but to our knowledge
no published reports of toxicity associated with trovaflox-
acin. We describe a patient in whom severe acute hepatitis
developed while he was receiving trovafloxacin for chronic
sinusitis. This 66-year-old man presented with nausea, vom-
iting, malaise, and abdominal distention. He had taken 100
mg of trovafloxacin daily for four weeks for treatment of
refractory chronic sinusitis. His medical history included hy-
pertension, gout, osteoarthritis, and chronic idiopathic an-
gioedema. He had been treated with losartan, metoprolol,
hydrochlorothiazide, allopurinol, nabumetone, and doxepin
for several years. He rarely drank alcohol.
On examination, the patient was febrile and had mild
tachypnea. His abdomen was markedly distended but not
tender; bowel sounds were decreased. There was no jaun-
dice, ascites, or organomegaly. The initial white-cell count
was 8000, with 16 percent eosinophils; the serum aspartate
aminotransferase level, 537 IU per liter; the serum alanine
aminotransferase level, 841 IU per liter; the direct biliru-
bin level, 1.0 mg per deciliter; the total bilirubin level, 1.6
mg per deciliter; the alkaline phosphatase level, 111 IU per
liter; the blood urea nitrogen level, 30 mg per deciliter;
and the creatinine level, 3.2 mg per deciliter. Tests for hep-
atitis A, B, and C infection were negative. A computed to-
mographic scan of the abdomen showed fluid adjacent to the
liver and spleen, bilateral pleural effusions, and consolida-
tion at the base of the right lung, but no hepatic parenchy-
mal abnormality. Ultrasonography of the abdomen showed
coarse echogenicity, a finding consistent with necrosis. Nei-
ther gallstones nor ascites was seen; the bile ducts were not
distended. A biopsy specimen of the liver showed centri-
lobular and focal periportal necrosis and eosinophilic infil-
tration (Fig. 1). The sinusoids were dilated and contained
lymphocytes and eosinophils; many hepatocytes were un-
dergoing mitosis. A stool sample was positive for Clostrid-
ium difficile toxin, which may have accounted for the per-
sistent abdominal distention.
Use of trovafloxacin was discontinued, while use of the
other medications was continued. The patient was treated
with prednisone for the hepatitis and metronidazole for
the C. difficile infection. His hepatic and renal function re-
turned to normal, and the eosinophilia gradually resolved.
This is a biopsy-proved case of hepatic toxicity associated
with the use of trovafloxacin. We are indebted to Dr. Peter
B. Kelsey for permitting us to study this patient.
HENRY J.L. CHEN, M.D.
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Boston, MA 02114
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Figure 1. Biopsy Specimen of the Liver (Hematoxylin and
Eosin).
The biopsy specimen of the liver (¬156) shows centrilobular
necrosis, with a mixed cellular infiltrate of eosinophils, polymor-
phonuclear leukocytes, and mononuclear cells. There is marked
hepatic necrosis out of proportion to the extent of inflamma-
tion, a finding that suggests toxic injury. The inset (¬312) shows
four eosinophils (arrows).
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